NFL Biosciences

[anonymous]

NFL-101 is NFL Biosciences current core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.
2 ongoing studies, a P2a with existing treatment and a P2/3 (NCT04571216) comparing placebo and 2 nfl101 dosage with results by the end of year. The retrospective study shows 3x greater efficacy than all existing treatments (patches and champix): 56% at 6 months and 44% over one year in 290 patients.
The company FR0014003XT0 capitalizes less than 20 million while the target market is 6 billion, is there not a big stock market anomaly? If anyone knows the value...

 

[TioBen]

NFL-101 is NFL Biosciences current core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.
2 ongoing studies, a P2a with existing treatment and a P2/3 (NCT04571216) comparing placebo and 2 nfl101 dosage with results by the end of year. The retrospective study shows 3x greater efficacy than all existing treatments (patches and champix): 56% at 6 months and 44% over one year in 290 patients.
The company FR0014003XT0 capitalizes less than 20 million while the target market is 6 billion, is there not a big stock market anomaly? If anyone knows the value...

 

[anonymous]

Yes,its an anomaly.
But its changing since 1 week.
Volumes are growing.
Good opportunity to get it, at this low Price.

 

[anonymous]

Nfl biosciences has received approval from the European Patent Office for the issuance of its patent (17 716 853.1 ) relating to NFL-101, a botanical drug candidate composed of natural proteins extracted from tobacco leaves, free of nicotine, and primarily intended for smoking cessation. This patent will protect the innovation on which NFL-101 is based until 2036 in 17 European countries. At the same time, the EMA (European Medicines Agency), as part of the request for scientific advice initiated by NFL Biosciences, validated the clinical development plan for NFL-101.